Bristol-Myers Squibb Company (BMS) recently announced that 97 percent of hepatitis C patients also infected with HIV were cured of the liver virus after 12 weeks of treatment with the company’s dacatasvir and Gilead Sciences’ Sovaldi.
Historically, patients with chronic hepatitis C virus (HCV) coinfected with HIV have been challenging to treat, largely due to potential drug-to-drug interactions between the therapy regimens used to treat each infection. Results from the company’s ALLY-2 study could help put BMS’ hepatitis C program back on track in the US.
The mid-stage trial included new patients and those who did not respond to prior treatment. In the trial, 149 of 153 were cured of hepatitis C regardless of what other anti-viral regimens they were on for HIV.
“The results of ALLY-2 signal that nearly all HIV-HCV coinfected patients in the study could be cured of hepatitis C with a 12-week regimen on daclatasvir and sofosbuvir,” said David Wyles, MD, ALLY-2 Lead Investigator and Associate Professor of Medicine in the Department of Medicine, Division of Infectious Diseases at the University of California San Diego. “The trial demonstrated the dosing flexibility afforded by the daclatasvir-sofosbuvir regimen did not require alteration of HIV medications because of potential drug-drug interactions. This is a paramount consideration for clinicians treating this patient population.”
Roughly 300,000 Americans with HIV also suffer from HCV, making them prone to more rapid progression to liver failure, according to the CDC.
“While substantial strides have been made in the battle against hepatitis C, a significant number of patients with complicated disease and treatment histories need additional treatment options to help them achieve hepatitis C cure,” said Douglas Manion, MD, head of Specialty Development, Bristol-Myers Squibb. “The ALLY-2 results show that daclatasvir paired with sofosbuvir produced high cure rates in this trial regardless of the coinfected patients’ HCV genotype.”
Source: Bristol-Myers Squibb Company